| Literature DB >> 30538678 |
Sarita Manandhar1,2, Anjana Singh3, Ajit Varma2, Shanti Pandey4, Neeraj Shrivastava2,5.
Abstract
Staphylococcus aureus, a notorious human pathogen, is a major cause of the community as well as healthcare associated infections. It can cause a diversity of recalcitrant infections mainly due to the acquisition of resistance to multiple drugs, its diverse range of virulence factors, and the ability to produce biofilm in indwelling medical devices. Such biofilm associated chronic infections often lead to increase in morbidity and mortality posing a high socio-economic burden, especially in developing countries. Since biofilm formation and antibiotic resistance function dependent on each other, detection of biofilm expression in clinical isolates would be advantageous in treatment decision. In this premise, we attempt to investigate the biofilm formation and its association with antibiotic resistance in clinical isolates from the patients visiting tertiary health care hospitals in Nepal. Bacterial cells isolated from clinical samples identified as S. aureus were examined for in-vitro biofilm production using both phenotypic and genotypic assays. The S. aureus isolates were also examined for susceptibility patterns of clinically relevant antibiotics as well as inducible clindamycin resistance using standard microbiological techniques and D-test, respectively. Among 161 S. aureus isolates, 131 (81.4%) were methicillin resistant S. aureus (MRSA) and 30 (18.6%) were methicillin sensitive S. aureus (MSSA) strains. Although a majority of MRSA strains (69.6%) showed inducible clindamycin resistance, almost all isolates (97% and 94%) were sensitive toward chloramphenicol and tetracycline, respectively. Detection of in vitro production of biofilm revealed the association of biofilm with methicillin as well as inducible clindamycin resistance among the clinical S. aureus isolates.Entities:
Keywords: Staphylococcus aureus; antibiotic resistance; biofilm; ica genes; inducible clindamycin resistance
Year: 2018 PMID: 30538678 PMCID: PMC6277500 DOI: 10.3389/fmicb.2018.02749
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
FIGURE 1D-test showing inducible clindamycin resistance.
FIGURE 2(A) Biofilm producing isolates with black colonies on Congo Red Agar medium. (B) Biofilm production by tube method. Tube 1:+++, Tube 2:++, Tube 3:+, Tube 4: –, Tube 5: blank. (C) Biofilm production by Tissue Culture Plate method.
Antimicrobial Susceptibility Test (AST) results of MRSA and MSSA strains.
| Antibiotics | Potency (μg/disk) | Resistant cases | ||
|---|---|---|---|---|
| MRSA ( | MSSA ( | Total ( | ||
| Cefoxitin | 30 | 131(100%) | 0 | 131(81.4%) |
| Penicillin | 10 | 126(96.2%) | 27(90%) | 158(98.1%) |
| Tetracycline | 30 | 8(6.1%) | 1(3.3%) | 9(5.5%) |
| Clindamycin | 2 | 16(12.2%) | 0 | 16(10%) |
| Chloramphenicol | 30 | 4(3.1%) | 0 | 4(2.4%) |
| Ciprofloxacin | 5 | 102(77.9%) | 17(56.7%) | 119(73.9%) |
| Erythromycin | 15 | 110(84%) | 17(56.7%) | 127(78.9%) |
| Cotrimoxazole | 1.25/23.75 | 72(55%) | 18(60%) | 90(55.9%) |
| Gentamicin | 10 | 58(44.3%) | 9(30%) | 67(41.6%) |
Prevalence of Inducible Clindamycin Resistance (ICR) in MRSA and MSSA strains.
| Phenotypes∗ | MRSA | MSSA | Total | |||
|---|---|---|---|---|---|---|
| ( | % | ( | % | ( | % | |
| E-S, CD-S | 20 | 12.4 | 12 | 7.5 | 32 | 19.9 |
| E-R, CD-R (constitutive MLSB) | 15 | 9.3 | 2 | 1.2 | 17 | 10.5 |
| E-R, CD-S (inducible MLSB, | 42 | 26.1 | 14 | 8.7 | 56 | 34.8 |
| E-R, CD-S (MS, | 54 | 33.6 | 3 | 1.9 | 57 | 35.5 |
| Total | 131 | 81.4 | 30 | 18.6 | 161 | 100 |
Biofilm production among Staphylococcal isolates by Tube method (TM).
| Biofilm production | MRSA | MSSA | Total | |
|---|---|---|---|---|
| Strong (+++) | 18 (11.2%) | 1 (0.6%) | 19 (5.6%) | 0.003 |
| Moderate (++) | 27 (16.8%) | 15 (9.3%) | 42 (26.1%) | |
| Weak (+/-) | 86 (53.4%) | 14 (46.7%) | 100 (62.1%) | |
In-vitro detection of biofilm production by MRSA and MSSA strains by commonly used phenotypic assays (CRA, TM, and TCP), and genotypic assay (detection of icaAD genes).
| Method | Biofilm | MRSA | MSSA | Total | |
|---|---|---|---|---|---|
| Positive | 2(1.2%) | 1(0.6%) | 3(1.9%) | 0.5092 | |
| Negative | 129(80.1%) | 29(18.0%) | 158(98.1%) | ||
| Positive | 45(28.0%) | 16(9.9%) | 61(37.9%) | 0.0532 | |
| Negative | 86(53.4%) | 14(8.7%) | 100(62.1%) | ||
| Positive | 70(43.5%) | 14(8.7%) | 84(52.2%) | 0.5032 | |
| Negative | 61(37.9%) | 16(9.9%) | 77(47.8%) | ||
| Positive | 29(18.0%) | 16(9.9%) | 45(28%) | 0.0006 | |
| Negative | 102(63.4%) | 14(8.7%) | 116(72%) | ||
Antimicrobial Resistance Pattern and Biofilm Formation in S. aureus Isolates.
| Antibiotics | Biofilm detection methods | ||
|---|---|---|---|
| TM ( | TCP ( | ||
| Penicillin | 59 (96.7%) | 77(91.7%) | 43(95.6%) |
| Cefoxitin | 45(73.8%) | 46(54.8%) | 29(64.4%) |
| Tetracycline | 3(4.9%) | 3(3.6%) | 3(6.6%) |
| Clindamycin | 2(3.3%) | 6(7.1%) | 3(6.6%) |
| Chloramphenicol | 2(3.3%) | 1(1.2%) | 2(4.4%) |
| Ciprofloxacin | 32(52.5%) | 70(83.3%) | 31(68.9%) |
| Erythromycin | 29(47.5%) | 36(42.9%) | 28(62.2%) |
| Cotrimoxazole | 20(32.8%) | 24(28.6%) | 26(57.8%) |
| Gentamicin | 17(27.9%) | 20(23.8%) | 22(48.9%) |